Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models

被引：1
|
作者：
Mahdi, Amira F.
Ashfield, Niall
Conlon, Neil T.
Crown, John
Collins, Denis M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-07-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-16
引用
收藏
页数：3
相关论文
共 50 条
  • [21] HER2-targeted therapies in cancer: a systematic review
    Zhu, Kunrui
    Yang, Xinyi
    Tai, Hebei
    Zhong, Xiaorong
    Luo, Ting
    Zheng, Hong
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [22] HER2-targeted therapies in cancer: a systematic review
    Kunrui Zhu
    Xinyi Yang
    Hebei Tai
    Xiaorong Zhong
    Ting Luo
    Hong Zheng
    Biomarker Research, 12
  • [23] The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
    Freudenberg, Jaclyn A.
    Wang, Qiang
    Katsumata, Makoto
    Drebin, Jeffrey
    Nagatomo, Izumi
    Greene, Mark I.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 87 (01) : 1 - 11
  • [24] Activating HER2 mutations promote oncogenesis and resistance to HER2-targeted therapies in breast cancer
    Zuo, Wen-Jia
    Jiang, Yi-Zhou
    Yu, Ke-Da
    Shao, Zhi-Ming
    CANCER RESEARCH, 2015, 75
  • [25] Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
    Shuai Li
    Jiayi Wu
    Ou Huang
    Jianrong He
    Li Zhu
    Weiguo Chen
    Yafen Li
    Xiaosong Chen
    Kunwei Shen
    BMC Cancer, 21
  • [26] The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers
    Lemieux, J.
    Clemons, M.
    Provencher, L.
    Dent, S.
    Latreille, J.
    Mackey, J.
    Pritchard, K. I.
    Rayson, D.
    Verma, Sh.
    Verma, Su.
    Wang, B.
    Chia, S.
    CURRENT ONCOLOGY, 2009, 16 (05) : 316 - 325
  • [27] A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer
    Munster, Pamela N.
    Miller, Kathy
    Krop, Ian E.
    Dhindsa, Navreet
    Reynolds, Joe
    Geretti, Elena
    Niyikiza, Clet
    Nielsen, Ulrik
    Hendriks, Bart
    Wickham, Thomas J.
    Moyo, Victor M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
    Dent, Susan F.
    Morse, Amber
    Burnette, Sarah
    Guha, Avirup
    Moore, Heather
    CURRENT ONCOLOGY REPORTS, 2021, 23 (11)
  • [29] Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    Sharial, M. S. N. Mohd
    Crown, J.
    Hennessy, B. T.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3007 - 3016
  • [30] Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer
    Zhao, Ming
    Scott, Stephen
    Evans, Kurt
    Yuca, Erkan
    Murthy, Rashmi
    Avogadri-Connors, Francesca
    Cutler, Richard
    Lalani, Alshad S.
    Piha-Paul, Sarina
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2017, 77
12345